feed,title,long_url,short_url
Benzinga,Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%,https://www.benzinga.com/pressreleases/20/09/g17582047/late-breaking-esmo-presentation-shows-libtayo-cemiplimab-monotherapy-increases-overall-survival-in,https://j.mp/2FSBrUv
